Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Autistic disorder

Pervasive developmental disorder If there is a history of autistic disorder or another pervasive developmental disorder, the additional diagnosis of schizophrenia is made only if prominent delusions or hallucinations are also present for at least a month (or less if successfully treated). [Pg.552]

For obvious reasons, neurodevelopmental illnesses usually appear at birth or in early childhood. It is during these early years that the connections that form brain circuitry are established. Some of the best-known examples of neurodevelopmental illnesses include cerebral palsy, phenylketonuria, and the autistic disorders. [Pg.23]

Pervasive Developmental Disorders. Children with autism or one of the other pervasive developmental disorders can be impulsive and inattentive much like those with ADHD. However, the severe social disability and language problems of children with an autistic disorder usually far exceed that of ADHD. These differences are usually sufficient to clarify the diagnosis. When one is unsure, neuropsychological testing can help clarify matters. [Pg.238]

Sacco, R., Papaleo, V., Hager, J., Rousseau, F., Moessner, R., Militerni, R., Bravaccio, P., Trillo, S., Schneider, C., Melmed, R., Elia, M., Curatolo, P., et al. (2007). Case-control and family-based association studies of candidate genes in autistic disorder and its endophenotypes TPH2 and GLO 1. BMC Med. Genet. 8,11. [Pg.149]

Yorbik, O., Sayal, A., Akay, C., Akbiyik, D. I., and Sohmen, T. (2002). Investigation of antioxidant enzymes in children with autistic disorder. Prostglandins Leukot. Essent. [Pg.154]

S., Montecchi, E, Palermo, M., Pascucci, T., Puglisi-Allegra, S., Reichelt, K.-L., Conciatori, M., Marino, R., Quattrocchi C.C. Baldi, Zelante A., Gasparini P. and Keller E. (2001) Reelin gene alleles and haplotypes as a predisposing factor to Molecular Psychiatry 6 150-159 autistic disorder. [Pg.17]

Arnold, L.E., Aman, M.G., Martin, A., Collier-Crespin, A., Vitiello, B., Tierney, E. Asarnow, R., Bell-Bradshaw, F., Freeman, B.J., Gates-Ulanet, P., Klin, A., McCracken, J.T., McDougle, C.J., McGough, J.J., Posey, D.J., Scahill, L., Swiezy, N.B., Ritz, L., and Volkmar, F. (2000). Assessment in multisite randomized clinical trials of patients with autistic disorder the Autism RUPP Network. Research Units on Pediatric Psychopharmacology./Autism Dev Disord 30 99-111. [Pg.92]

Kim, S.J., Cox, N., Courchesne, R., Lord, C., Corsello, C., Natacha Akshoomoff, N., Guter, S., Leventhal, B.L., Courchesne, E., and Cook, E.H. (2002) Transmission disequilibrium mapping in the serotonin transporter gene (SLC6A4) region in autistic disorder. Amer J Hum Genet 2002, in press. [Pg.94]

Although childhood cases are rare (McKenna et ah, 1994), schizophrenia has been identified in children since its earliest descriptions. Despite this, the nosological status of schizophrenia in children was controversial for many years, and the Diagnostic and Statistical Manual of Mental Disorders, 2nd ed. (DSM-II) category childhood schizophrenia included other psychotic disorders in children as well as autistic disorder, limiting the usefulness of early studies. The landmark studies by Kolvin (1971), however, clearly differentiated schizophrenia with onset in childhood from pervasive developmental disorders. [Pg.184]

Preliminary studies on pharmacological manipulation of the serotonergic system in autism suggest that acute depletion of the 5-HT precursor tryptophan can exacerbate many behavioral symptoms of autistic disorder (McDougle et ah, 1996). McBride et al. (1989) showed decreased central 5-HT responsiveness in autistic adults via blunted prolactin response to fenfluramine, a 5-HT-releasing agent. [Pg.205]

Gordon, C.T, State, R.C., Nelson, J.E., Hamburger, S.D., and Ra-poport J.L. (1993) A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50 441—447. [Pg.207]

Hollander, E., Novotny, S., Allen, A., Aronowitz, B., and DeCaria, C. (2000) The relationship between repetitive behaviors and growth hormone response to sumatriptan challenge in adult autistic disorders. Neuropsychopharmacology 22 163-167. [Pg.207]

McBride, P.A., Anderson, G.M., Hertzig, M.E., Sweeney, J.A., Kleam J., Cohen, D.J., and Mann, J.J. (1989) Serotonergic response in male young adults with autistic disorder. Arch Gen Psychiatry 46 205-212. [Pg.208]

McDougle, C.J., Naylor, S.T., Cohen, D.J., Volkmar, F.R., Heninger, G.R., and Price, L.H. (1996) A double-blind placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53 1001-1008. [Pg.208]

Clonidine treatment of hyperactive and impulsive children with autistic disorder. / Clin Psychopharmacol 12 322-327. [Pg.272]

Cook, E.H., Jr., Rowlett, R., Jaselskis, C., and Leventhal, B.L. (1992) Fluoxetine treatment of children and adults with autistic disorder and mental retardation. / Am Acad Child Adolesc Psychiatry 31 739-745. [Pg.280]

Clozapine Dibenzodiazepine 25-900 Low 100 Treatment-resistant illnesses Schizophrenia Bipolar disorder Autistic disorder Kumra et ah, 1996 Kowatch et ah, 1995 Zuddas et ah, 1996... [Pg.329]

Haloperidol Butyrophenone 0.25-15 High 2 Autistic disorder Conduct disorder Schizophrenia Tic disorders Anderson et ah, 1984 Campbell et ah, 1984 Spencer and Campbell, 1984 Shapiro et ah, 1989... [Pg.329]

Wudarsky, M., Nicolson, R., Hamburger, S.D., Spechler, L., Goch-man, R, Bedwell, J., Lenane, M.C., and Rapoport, J.L. (1999) Elevated prolactin in pediatric patients on typical and atypical antipsychotics. / Child Adolesc Psychopharmacol 9 239—245. Zuddas, A. Tedda, M.G., Fratta, A., Muglia, P., and Cianchetti, C. (1996) Clinical effects of clozapine on autistic disorder [letter]. Am Psychiatry 153 738. [Pg.340]

The assessment and treatment of autistic disorder and other pervasive developmental disorders (PDDs) requires a multidisciplinary team approach. Initial interventions are largely based on educational programming and behavior management principles, particularly for preschool- and school-aged children and adolescents. Speech therapy is usually essential and physical and occupational therapy are often needed as well. Despite these extensive therapeutic efforts, many children, adolescents, and adults with PDDs remain significantly impaired. Under these conditions, drug treatment is often necessary and appropriate. [Pg.563]

Drugs that have primary effects on the core social impairment of autistic disorder and other PDDs have not yet been developed. Currently, the pharmacotherapy of this group of disorders involves the identification and treatment of associated symptoms, including motor hyperactivity, inattention, irritability, aggression toward self, others, or the environment, and interfering repetitive thoughts and behavior. Improvement in some aspects of social behavior can occur as a result of a reduction in these associated target symptoms. [Pg.563]

Autistic disorder is characterized by a severe impairment in the development of social interaction and corn-... [Pg.563]

Beginning in the 1960s, a number of agents, including lysergic acid diethylamide, methysergide, levodopa, triiodothyronine, imipramine, and 5-hydroxytrypto-phan were studied in autistic disorder. Many of these trials were limited by the lack of diagnostic standard-... [Pg.567]


See other pages where Autistic disorder is mentioned: [Pg.471]    [Pg.89]    [Pg.93]    [Pg.206]    [Pg.412]    [Pg.563]    [Pg.563]    [Pg.563]    [Pg.564]    [Pg.564]    [Pg.564]    [Pg.564]    [Pg.565]    [Pg.565]    [Pg.566]    [Pg.567]    [Pg.567]    [Pg.567]   
See also in sourсe #XX -- [ Pg.22 ]




SEARCH



© 2024 chempedia.info